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Abstract 
The effect of phytochemical tannic acid on Methicillin Resistant Staphylococcus aureus (MRSA) three clinical strains was 
studied individually and in combination with western antibiotic fusidic acid. The two drugs were synergistic to each other 
and the combined effect of the two drugs could delay or prevent the occurrence of adaptive mutations in MRSA. The 
possible mechanism might be the phytochemical tannic acid could potentiate the effect of fusidic acid and/or acts 
alternative target that results in lysis of bacteria. In this study, it was found that the mutants result from the continuous 
exposure of sub-minimal inhibitory concentration (MIC) of fusidic acid revealed over active efflux pump as measured by 
ethidium bromide (EtBr) accumulation assay. However, the parent strains have no efflux pump activity. Therefore, it can 
be concluded  efflux pump if they 
are being exposed by sub-MIC concentrations of western antibiotic (fusidic acid). Efflux modulating activity of tannic 
acid was tested against the strains with over active efflux pump activity. It was noticed that EtBr accumulation was 
increased with over time when the adapted strains were being exposed by sub-MIC concentrations (0.3 and 0.6 MIC) of 
tannic acid, meaning that phytochemical tannic acid has efflux modulating activity against MRSA strains that results in 
decreased in MIC of partner drug and thus, preventing its adaptive mutation. 
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1. Introduction 
MRSA becomes well-known pathogen because of its resistance adaptation mechanisms. Among them, 
efflux pump activity that pumps out of incoming antibiotics is one of the accepted mechanisms that confer the 
increased in MIC in MRSA [1, 2]. The overactive efflux pump activity can result from systems that are 
resistance to a specific class of antibiotics or to a large number of unrelated antimicrobial agents, resulting in 
a multidrug-resistant phenotype [3, 4].  
Much attention has given in the search of new compounds which have the ability to inhibit or modulate 
efflux activity of multidrug resistance bacteria when used in combination, thereby increasing the activity of 
the partner drugs [5]. Some of the phytochemicals have been reported for their activities to modulate efflux 
activities of Multidrug resistant bacteria. For instance, ethyl gallate derived from the plant called Caesalpinia 
spinosa can potentiate the activitie -lactams antibiotics [6]. Similarly, Epicatechin gallate and 
Epigallocatechin gallate derived from Camellia sinensis have the activity to modify the effects of norfloxacin, 
-lactams [7, 8]. Antibacterial action against MRSA and their ability to reduce the 
MIC of partner drug when used in combination draws critical attention in phytochemicals research as a new 
alternative treatment approach for complicated anti-bacterial therapy [9].  
Tannic acid or tannin is a polyphenol which has antibacterial activity against MRSA [10]. It has shown to 
inhibit or delay the adaptive resistance in MRSA [11]. The synergism with antibiotics against MRSA clinical 
strains has also reported previously [12]. The possible efflux inhibiting activity against MRSA was 
demonstrated by using universal efflux substrate ethidium bromide in a Rotor Gene 3000TM as described by 
Ramalhete et al [13].  
2. Materials and Methods 
Tannic acid powder (98% purity value, Cat. No. 16201) and fusidic acid powder (98% purity value, Cat. 
No. F0756-1G) were purchased from Sigma-Aldrich, Singapore. Stock solutions were prepared and stored at -
20 ºC for subsequent use up to 1 month. The bacterial strains were grown at 37 ºC in Iso-Sensitive (IS) Broth 
with aeration. IS broth and Agar (Oxoid Pte Ltd, Singapore) were used throughout the study.  
2.1. Bacterial Strains 
Three clinical strains of MRSA collected from National University Hospital, Singapore were used in this 
study. The strains initially exhibited no efflux activity based on EtBr accumulating assay and their MICs were 
to sub-MIC concentrations of fusidic 
acid for a period of 10 continuous days and the MICs were increased up to 32 times and named according to 
the drug concentrations that they were being exposed. For every strain, a total of 5 sub-MIC concentrations 
(0.8, 0.6, 0.5, 0.4 and 0.2) of fusidic acid were used to expose and named accordingly.  For example, the 
MRSA clinical strain 1 that was being exposed with 0.8 MIC of fusidic acid alone for a period of ten days and 
it is named as C1_80. 
2.2. Determination of Minimum Inhibitory Concentrations (MICs) 
The MICs of the fusidic acid and tannic acid were 0.25 μg/ml and 256 μg/ml respectively for all clinical 
strains as determined by the microplate microbroth dilution method according to Clinical and Laboratory 
Standards Institute (CLSI) recommendations [9]. MRSA ATCC 43300 strain was used as control strain. 
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2.3. Real-Time Ethidium Bromide Accumulation Assay  
The activity of drug combination against potential bacteria efflux system was assessed by the semi-
automated EtBr method as previously described by Ramalhete et al using a Rotor-Gene 3000TM Thermal 
Cycler with real-time analysis software (Corbett Research, Sydney, Australia) [13]. Briefly, strains were 
incubated in IS broth until they reached an optical density at 600 nm (OD600) of 0.6 and were then centrifuged 
at 13,000 rpm for 3 min. Bacterial pellets were re-suspended and were washed twice in phosphate-buffered 
saline (PBS) (pH 7.4) containing glucose to yield a final concentration of 0.4%. The OD600 was adjusted with 
PBS-glucose to 0.6, the suspension was mixed by vortex and 50 μL of the suspension was transferred to 0.2 
ml tubes, followed by addition of 45 μL of PBS containing 1 μg/ml of EtBr (Sigma-Aldrich, Singapore).The 
tubes were placed in a Rotor-Gene 3000TM Thermal Cycler and the amount of fluorescence representing 
accumulated EtBr by the bacterium was monitored on a real-time basis.  
From the real-time data using relative fluorescence (RF) over a 30-min period of EtBr accumulation, the 
slope of the accumulation-time curve was calculated by linear regression analysis (Microsoft Excel). The 
greater the difference in the slope between the strains treated with the phytochemical and the strain without 
any compound was indicative of the activity of the compound to inhibit the efflux of EtBr. The relative final 
fluorescence (RFF) of the last time point (60 min) of the EtBr accumulation assay was also calculated 
according to the formula: 
RFF = FR treated  RFuntreated 
RFtreated is the RF at the last time point of the EtBr retention curve of bacterial strains with the 
phytochemical and RFuntreated is the RF at the last time point of the EtBr retention curve of the strain without 
any compound [13]. 
Table 1. Minimum inhibitory concentrations (MICs) fusidic acid and tannic acid against parent MRSA clinical strains and their adapted 
strains 
Strains Fusidic Acid MIC × 1x 
Tannic Acid MIC 
(μg/ml) EtBr (30mis) 
C1_Ori 1 (0.25 μg/ml) 256 36.2457 
C1_80 32x 256 0.7834 
C1_60 16x 256 0.7161 
C1_50 16x 256 0.6597 
C1_40 16x 256 0.8057 
C1_20 16x 256 0.9804 
C2_Ori 1x (0.25 μg/ml) 256 21.2270 
C2_80 32x 256 1.3630 
C2_60 16x 256 1.3931 
C2_50 16x 256 1.1804 
C2_40 32x 256 1.2948 
C2_20 16x 256 0.6555 
C3_Ori 1x (0.25 μg/ml) 256 21.5881 
C3_80 32x 256 0.5807 
C3_60 32x 256 2.1850 
C3_50 16x 256 1.6849 
C3_40 16x 256 1.0849 
C3_20 16x 256 1.4894 
3. Results 
To determine efflux-modulating activity, it is necessary to use a concentration of any potential efflux pump 
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inhibitor (EPI) that is below its bactericidal concentration [14]. Selection of this concentration was depended 
on the MIC of individual drug. Sub-MIC concentrations of 0.3 and 0.6 MIC values were chosen to test against 
EPI activity of MRSA. As shown in table 1, the MICs of fusidic acid in the original strains were 0.25 μg/ml 
for all strains. However, after being exposure to sub MIC concentrations, the MICs were increased up to 32 
times than original strain. Tannic acid has unique MIC values against all 3 MRSA clinical strains and also 
against their adapted strains that were being exposed to sub-MIC fusidic acid concentrations. It was noticed 
that 0.3 and 0.6 MIC of tannic acid have no significant bactericidal values against tested bacterial strains and 
thus therefore it was used in the EtBr accumulation assay. 




















C1_Ori   0.73   33.7557   
C1_80 0.17 0.50  5.0516 14.4629  12.36648 32.5205 
C1_60 0.22 0.65  7.1689 15.9955  13.02547 35.1715 
C1_50 0.24 0.47  6.4241 13.2404  15.11194 27.6403 
C1_40 0.21 0.44  5.9042 13.5708  14.14972 33.1397 
C1_20 0.22 0.51  5.7208 15.5274  16.41243 35.0759 
C2_Ori   0.57   20.4270   
C2_80 0.18 0.40  4.9728 10.6995  17.21774 28.2127 
C2_60 0.18 0.22  4.4383 5.4000  14.02616 28.0528 
C2_50 0.20 0.48  4.9738 12.9460  16.18441 31.1137 
C2_40 0.15 0.37  3.8846 9.8390  19.33627 34.1521 
C2_20 0.19 0.55  4.8293 14.9557  16.1628 32.1715 
C3_Ori   0.81   23.9643   
C3_80 0.23 0.58  6.6033 15.8728  19.17639 32.1738 
C3_60 0.26 0.40  5.2063 10.1692  17.17538 30.1828 
C3_50 0.21 0.50  5.2435 13.5258  21.19573 36.2111 
C3_40 0.28 0.60  6.5533 16.0622  18.22613 31.2391 
C3_20 0.33 0.50  7.2871 13.3567  18.24931 37.2561 
TA, tannic acid 
a Slope of accumulation of EtBr by parent strain (without treated with tannic acid) and the efflux exhibiting adapted strains (treated 
with 0.3 and 0.6 MIC of tannic acid)  
b Relative final fluorescence (RFF) = RFtreated  RFuntreated, where RFtreated is the relative final fluorescence (RF) at the last time point of 
the EtBr retention curve (at 30 mins) in the presence of sub-MIC concentrations (0.3 and 0.6 MIC) of tannic acid and RFuntreated is the 
RF at the last time point of the EtBr retention curve of the untreated control (without tannic acid) 
c Relative final fluorescence of parent strains at the last time point of the EtBr accumulation curve 
d Relative final fluorescence (RFF) = RFtreated  RFuntreated, where RFtreated is the relative final fluorescence (RF) at the last time point of 
the EtBr retention curve (at 60 mins) in the presence of sub-MIC concentration of tannic acid and RFuntreated is the RF at the last time 
point of the EtBr retention curve of the untreated control (without tannic acid) 
3.1. Determination of Efflux Action by EtBr Accumulation Assay 
Accumulation of EtBr by the MRSA 3 clinical strains and their adapted strains were investigated with the 
methods described by Ramalhete et al [13]. It was noticed that the accumulation was increased in parent 
MRSA clinical strains compare with the adapted strains, suggesting that no overactive efflux activities take 
places. However, the prominent reduced in EtBr level (overall less than 1) was noticed over a period of 30 
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minutes in adapted strains, suggesting the over active efflux activities as EtBr is universal efflux substrate.  
3.2. Effect of Tannic Acid on Efflux Exhibiting Strains 
Efflux pump inhibiting activity of tannic acid at two sub-MIC concentrations (0.3 and 0.6 MICs) was 
evaluated against MRSA 3 clinical strains and their adapted strains which showed higher activity of efflux 
pump in EtBr accumulation assay. The strains were exposed to sub-MIC concentrations of fusidic acid alone 
for 10 continuous days, resulting in increased in MIC of fusidic acid up to 32 times compared to parent strain 
at Day 1. The possible mechanism behind this was evaluated by using already established method prescribed 
by Ramalhete et al [13].  
The results obtained from the semi-automated method, representing accumulation of EtBr by the MRSA 
strains are shown in table 2. The efflux inhibiting activity of tannic acid was concentration depended manner 
as the accumulation of EtBr is increased with the addition of 0.6 MIC of tannic acid compare to the results 
from 0.3 MIC of the compound. The similar results were found when the relative final fluorescence was 
calculated.  
4. Discussion 
The search for new antibacterial compounds become popular with the spread of multi-drug resistant 
bacteria and less antibiotics are effective to counteract those bacteria including multidrug MRSA [15]. 
Phytochemicals have been proposed as alternative drugs because of their antibacterial and anti-cancer effects. 
Moreover, phytochemicals have been reported as drug modulating or modifying agents when they are given 
together with other drugs [16]. Some studies have also reported that phytochemicals have the action to reverse 
cancer cells resistance to anti-cancer drugs [13]. Lewis et al stated that phytochemicals can even reverse or 
reduce the resistance of MDR bacterial strains to antibiotics [17]. Additionally, the side effects occurred by 
the phytochemicals is considerably less as they are derived from the plants [9]. All these reports are 
supporting phytochemicals as new therapeutic agents to fight for complex diseases.  
Tannic acid is a commercial form of tannin and it has been reported for antibacterial activity especially 
against Staphylococcus aureus [10]. The antibacterial action and its potentiating activity against MRSA 
strains were previously reported [12]. There have been proposed the possible mechanisms of tannic acid that 
achieves antibacterial effect, mainly targeting on bacterial cell wall [15] such as complex with cell wall 
protein, membrane disruption metal ion complexation and binds to adhesions [18, 19]. However, the specific 
mechanism of tannic acid how it works together with antibiotics is still needed to be approved.  
Efflux inhibiting activity of tannic acid was tested against three MRSA clinical strains which show efflux 
activities. Table 1 shows the MICs of MRSA clinical strains before and after exposure to sub-MIC 
concentrations of fusidic acid alone. Fusidic acid MICs increased up to 32 times than the parent strains over a 
period of ten incubation days. Tannic acid MICs were also checked for those parent strains and adapted 
clinical strains and found equal MIC. The sub-MIC adaptation of fusidic acid has no effect on tannic acid 
MIC at all.  
The EtBr accumulation assay was tested for both adapted strains and parent strains. It was found that the 
adapted strains have the ability to pump out of the incoming EtBr and the accumulation of EtBr inside the 
bacteria is low compare with parent strains which show increased accumulation. 
There will be two possible mechanisms behind this phenomenon. The first mechanism is the bacteria might 
have already encoded with efflux expressing proteins that are silent until the bacteria is getting insufficient 
antibiotic pressure, meaning that the bacteria can rapidly adapt to sub-MIC concentrations of antibiotic and 
thus, expressing over activity of already having efflux proteins. The second mechanism might be adaptation 
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of normally functioning proteins into efflux exhibiting proteins under continuous exposure of specific 
antibiotic pressure.  
Efflux modulating activity of tannic acid on MRSA strains was also investigated. Sub-MIC concentrations 
of tannic acid (0.3 and 0.6 MIC) were chosen and tested against MRSA strains which showed over activity of 
efflux pumps. As shown in Table 2, the EtBr accumulation was increased with addition of sub-MIC 
concentrations of tannic acid, especially at 0.6 MIC level. The accumulation was also in concentration-
dependent manner. One of the factors that enhance the effect of tannic acid on MRSA is that it is a gram 
positive bacterium that is lacking outer membrane. Therefore, it is much easier to bind cell wall proteins 
which exhibit efflux activity.  
In this study, it was found that the addition of sub-MIC concentrations of phytochemical tannic acid could 
inhibit or modulate the over activity of efflux pumps in MRSA strains resulting in increased accumulation of 
EtBr. Therefore, tannic acid can be used as potential efflux pump inhibitor against MRSA strains especially 
against the resistant strains adapted from sub-MIC exposure of antibiotic.  
5. Conclusion 
Phytochemical tannic acid is effective to modulate or inhibit the efflux activity of MRSA strains which 
were adapted from sub-MIC prolonged exposure of antibiotic.  
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